Q-omics provides the consensus-scored ID3 profile across patient tissues and cancer cell-line models. ID3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ID3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ID3 protein abundance shows 18,119 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, HNSC, and LUAD as cancer lineages where ID3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ID3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ID3 survival associations across molecular data types. ID3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ID3 RNA expression–survival associations across cancer types. High ID3 expression shows unfavorable associations in UVM, HNSC, BRCA and THCA, but favorable associations in UCEC and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ID3 RNA expression.
This table summarizes ID3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ID3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ID3 shows lower tumor expression in KICH, THCA, LUAD, LUSC and COAD and higher tumor expression in HNSC. The HNSC box plot shows higher ID3 RNA expression in tumor versus normal tissue (log2 FC = +1.576, t-test p < 0.001).
This table shows molecular features associated with ID3 in patient tissues and cancer cell lines. In patient samples, ID3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ID3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
